Kimura S, Seki M, Yoshida K, et al. NOTCH1 pathway activating mutations and clonal evolution in pediatric T‐cell acute lymphoblastic leukemia. Cancer Sci. 2019;110:784--794. 10.1111/cas.13859

1. INTRODUCTION {#cas13859-sec-0001}
===============

Although pediatric cases of T‐cell acute lymphoblastic leukemia (T‐ALL) have a cure rate exceeding 80% because of intensified chemotherapies and appropriate prognostic classifications, the outcome of T‐ALL patients with primary resistant or relapsed leukemia remains extremely poor.[1](#cas13859-bib-0001){ref-type="ref"}, [2](#cas13859-bib-0002){ref-type="ref"}, [3](#cas13859-bib-0003){ref-type="ref"} Recent insights into the biology of the disease have uncovered the genomic landscape of T‐ALL at diagnosis and defined T‐ALL subgroups.[4](#cas13859-bib-0004){ref-type="ref"}, [5](#cas13859-bib-0005){ref-type="ref"}, [6](#cas13859-bib-0006){ref-type="ref"}, [7](#cas13859-bib-0007){ref-type="ref"} However, the molecular basis of refractory/relapsed T‐ALL is largely unknown, except for the involvement of *NT5C2* mutations in relapsed T‐ALL.[8](#cas13859-bib-0008){ref-type="ref"}, [9](#cas13859-bib-0009){ref-type="ref"} In addition, the underlying clonal evolution leading to relapse and treatment resistance has been poorly studied in pediatric T‐ALL. In contrast, *NOTCH1* and/or *FBXW7* alterations, leading to constitutive activation of NOTCH1 signaling, are among the most common changes detected in T‐ALL patients.[6](#cas13859-bib-0006){ref-type="ref"}, [7](#cas13859-bib-0007){ref-type="ref"}, [10](#cas13859-bib-0010){ref-type="ref"} It is well known that alterations in the negative regulatory region (NRR), such as single nucleotide variations in the heterodimerization (HD) domain (HD‐SNV) and small in--frame insertions or deletions in the HD domain (Indel), lead to constitutive activation of NOTCH1 without ligand binding.[10](#cas13859-bib-0010){ref-type="ref"} NOTCH1 transcriptional activation is terminated by the proteasomal degradation of the NOTCH1 intracellular domain (NICD), which is induced by the proline, glutamic acid, serine, threonine--rich (PEST) domain recognition of the FBXW7‐SCF ubiquitin ligase complex.[11](#cas13859-bib-0011){ref-type="ref"} Alterations in the PEST domain of *NOTCH1* and *FBXW7* result in impaired degradation (ID) of NICD, leading to aberrantly prolonged NOTCH1 signaling.[11](#cas13859-bib-0011){ref-type="ref"}, [12](#cas13859-bib-0012){ref-type="ref"} Thus, there are 2 patterns of activation of NOTCH1 signaling: ligand--independent activation (LIA) of NOTCH1[10](#cas13859-bib-0010){ref-type="ref"}, [13](#cas13859-bib-0013){ref-type="ref"}, [14](#cas13859-bib-0014){ref-type="ref"}, [15](#cas13859-bib-0015){ref-type="ref"}, [16](#cas13859-bib-0016){ref-type="ref"} and ID of NOTCH1.[10](#cas13859-bib-0010){ref-type="ref"}, [11](#cas13859-bib-0011){ref-type="ref"}, [12](#cas13859-bib-0012){ref-type="ref"}, [17](#cas13859-bib-0017){ref-type="ref"}

Although activated NOTCH1 signaling constitutes the most predominant oncogenic event involved in the pathogenesis of T‐ALL, it is widely reported that T‐ALL patients with *NOTCH1* mutations have a favorable early therapeutic response[18](#cas13859-bib-0018){ref-type="ref"}, [19](#cas13859-bib-0019){ref-type="ref"} or outcome.[20](#cas13859-bib-0020){ref-type="ref"}, [21](#cas13859-bib-0021){ref-type="ref"}, [22](#cas13859-bib-0022){ref-type="ref"} However, some groups have reported no effect of *NOTCH1* mutations in the outcome of T‐ALL.[18](#cas13859-bib-0018){ref-type="ref"}, [23](#cas13859-bib-0023){ref-type="ref"}, [24](#cas13859-bib-0024){ref-type="ref"} Thus, the prognostic relevance of *NOTCH1* and/or *FBXW7* alterations is still controversial and may be protocol--specific. Moreover, the role of *NOTCH1* and/or *FBXW7* mutations in T‐ALL relapse is unclear. Despite recent advances in genome--wide analyses of diagnostic T‐ALL, little is known about the involvement of NOTCH1 in the relapse and progression of T‐ALL.[25](#cas13859-bib-0025){ref-type="ref"}, [26](#cas13859-bib-0026){ref-type="ref"} To investigate relapse--related genes in the progression of T‐ALL from diagnosis to relapse, especially the impact of *NOTCH1* and/or *FBXW7* alterations, we performed genetic analysis of 30 pediatric T‐ALL cases using whole--exome sequencing (WXS) and amplicon--based deep sequencing. Among these 30 cases, 12 cases were relapsed, and 11 diagnosis‐relapse paired cases available were further investigated to track the clonal evolution of the relapses.

2. MATERIALS AND METHODS {#cas13859-sec-0002}
========================

2.1. Patients and materials {#cas13859-sec-0003}
---------------------------

Thirty pediatric T‐ALL patients were enrolled in this study (Table [S1](#cas13859-sup-0010){ref-type="supplementary-material"}); results for 24 cases were reported previously.[6](#cas13859-bib-0006){ref-type="ref"} Analyzed samples were mainly offered from the Tokyo Children's Cancer Study Group (TCCSG) and the Japan Association of Childhood Leukemia Study (JACLS). All patients received Berlin‐ Frankfurt‐ Münster (BFM)--based chemotherapy. No minimal residual disease (MRD)--based risk stratification was performed. Written, informed consent was attained according to protocols approved by the Human Genome, Gene Analysis Research Ethics Committee of the University of Tokyo and other participating institutes. Peripheral blood, bone marrow blood and lymph node samples were collected from T‐ALL patients. Among 12 relapsed cases, relapse samples were available in 11 cases.

2.2. Whole--exome sequencing {#cas13859-sec-0004}
----------------------------

Whole--exome sequencing of diagnosis/relapse tumor and matched normal specimens was performed as previously described.[27](#cas13859-bib-0027){ref-type="ref"} Whole--exome capture was accomplished using SureSelect Human All Exon Kit V3 or V5 (Agilent Technology, Wilmington, DE) and was subjected to sequencing using HiSeq 2000 (Illumina, San Diego, CA) according to the manufacturer\'s protocol. Raw sequence data were processed using our in--house pipelines (Genomon 2.3.0, <https://github.com/Genomon-Project/GenomonPipeline>). Sequence reads with a mapping quality score \<25, base quality score \<30, or 5 or more mismatched bases were excluded. Relevant somatic mutations were filtered by excluding variants: (i) with incomplete open reading frame information; (ii) listed in the 1000 Genomes Project (May 2011 release), NCBI SNP database (dbSNP) build 131, National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) 5400, the Human Genome Variation Database (HGVD; October 2013 release) or our in--house SNP database; (iii) represented only in unidirectional reads; (iv) occurring in repetitive genomic regions; (v) having a variant allele frequency (VAF) \<.1; (vi) represented in \<5 reads in tumor samples; (vii) occurring in non--paired normal samples with VAF \>.0025; and (viii) occurring in paired normal samples with VAF ≥.1. Stringent criteria were used for calling mutations, requiring a *P*‐value for EBCall[28](#cas13859-bib-0028){ref-type="ref"} \<10^−4^ and a Fisher\'s *P*‐value \<10^−2^. Finally, mapping errors were removed by visual inspection using the Integrative Genomics Viewer browser.[29](#cas13859-bib-0029){ref-type="ref"}

2.3. Validation and detection of variant allele frequency for mutations detected by whole--exome sequencing using amplicon--based deep sequencing {#cas13859-sec-0005}
-------------------------------------------------------------------------------------------------------------------------------------------------

To validate the somatic mutations detected via WXS and to obtain more accurate VAF, we conducted amplicon--based deep sequencing at ≥1500× coverage (an average coverage of 7942×) using paired or trio DNA samples with MiSeq (Illumina). Because mutations in the 3′ untranslated region (UTR) of *NOTCH1* could not be detected using WXS given the predetermined bait design, primers were specifically designed (Table [S2](#cas13859-sup-0011){ref-type="supplementary-material"}). Target sequences were amplified using primers (Table [S3](#cas13859-sup-0012){ref-type="supplementary-material"}) tagged with *Not*I cleavage sites (AAGCGGCCGC), and the PCR products were ligated and fragmented for deep sequencing as described previously.[27](#cas13859-bib-0027){ref-type="ref"}

2.4. Analysis of T‐cell receptor rearrangements {#cas13859-sec-0006}
-----------------------------------------------

T‐cell receptor (TCR) rearrangements were determined at the TCR γ locus using T Cell Receptor Gamma Gene Rearrangement Assay 2.0 for ABI Fluorescence Detection (Invivoscribe, San Diego, CA, USA, \#1‐207‐101) according to the manufacturer\'s protocol.

2.5. Clonal analysis {#cas13859-sec-0007}
--------------------

Intrasample subpopulations were estimated using a hierarchical Beta Binomial emission model implemented in PyClone[30](#cas13859-bib-0030){ref-type="ref"} and the variational Bayesian beta mixture model in SciClone[31](#cas13859-bib-0031){ref-type="ref"} as described previously.[32](#cas13859-bib-0032){ref-type="ref"}, [33](#cas13859-bib-0033){ref-type="ref"} Mutations in indels, for which VAFs were poorly estimated, were not used for the analysis. We constructed branch--based phylogenetic trees using a bootstrap resampling technique implemented in ClonEvol.[34](#cas13859-bib-0034){ref-type="ref"} In each estimated clone, we defined minor clones and major clones as VAF \<.15 and VAF \>.15, respectively. To categorize the types of clonal evolution, we used a cutoff of VAF = .01.

2.6. Statistical analysis {#cas13859-sec-0008}
-------------------------

Statistical analyses were performed using R v3.4.0 software with the R packages Survival and maftools. Statistical significance was assessed using Student\'s 2--tailed *t* test, and resulting values were considered statistically significant at *P *\<* *.05.

3. RESULTS {#cas13859-sec-0009}
==========

3.1. Mutation detection at diagnosis and relapse of T‐cell acute lymphoblastic leukemia using whole--exome sequencing {#cas13859-sec-0010}
---------------------------------------------------------------------------------------------------------------------

We performed WXS on 30 cases of matched T‐ALL and normal (samples in complete remission phase) pairs, including 11 trios comprising samples at relapse, diagnosis, and normal (Table [S1](#cas13859-sup-0010){ref-type="supplementary-material"}). One T‐ALL case (TALL023) developed Langerhans cell histiocytosis (LCH) after achieving complete remission. In this case, the LCH cells are not only a derivative of the same ancestral clone but should be a branched clone from the one that already gave rise to T‐ALL, because the LCH cells have the same TCR rearrangements (Figure [S1](#cas13859-sup-0001){ref-type="supplementary-material"}D,E).[35](#cas13859-bib-0035){ref-type="ref"}, [36](#cas13859-bib-0036){ref-type="ref"} WXS was performed at an average coverage of 107.8× (range: 66.2‐201.9) (Figure [S2](#cas13859-sup-0002){ref-type="supplementary-material"}). All predicted SNVs were validated by amplicon--based deep sequencing (an average coverage of 7942×). Across the coding regions of 30 cases (total 41 samples: 30 samples at diagnosis and 11 samples at relapse), we detected 777 somatic mutations and structural variants in 515 genes (Tables [\[Link\]](#cas13859-sup-0003){ref-type="supplementary-material"}, [\[Link\]](#cas13859-sup-0004){ref-type="supplementary-material"}). Each T‐ALL sample at diagnosis harbored a mean of 16.9 somatic mutations (range: 3‐29), of which the mean number of mutations without synonymous SNV was 14.4 per sample (range: 2‐24). The mutation rate of relapse samples was significantly higher than that of samples at diagnosis, with a mean of 24.6 mutations per sample (range: 9‐40, *P *=* *.017; Figure [S3](#cas13859-sup-0003){ref-type="supplementary-material"}) and a mean of 20.5 mutations without synonymous SNV per sample (range: 9‐31; *P* = .014; Figure [1](#cas13859-fig-0001){ref-type="fig"}A). No difference was observed between non--relapsed and relapsed cases in the mutation rate of diagnostic T‐ALL samples (Figure [1](#cas13859-fig-0001){ref-type="fig"}A and Figure [S3](#cas13859-sup-0003){ref-type="supplementary-material"}). Because of the small sample number of cases analyzed, we could not find different features of immunophenotype and molecular subgroups between non--relapse and relapse samples (Table [1](#cas13859-tbl-0001){ref-type="table"} and Figure [S4](#cas13859-sup-0004){ref-type="supplementary-material"}). These subgroups were defined in our previous study[6](#cas13859-bib-0006){ref-type="ref"} based on expression data of whole--transcriptome sequencing. Consistent with previous reports, mutations in *NOTCH1* (66.7%), *FBXW7* (20.0%), *DNM2* (20.0%) and *PHF6* (20.0%) were common in T‐ALL samples at diagnosis (Figure [1](#cas13859-fig-0001){ref-type="fig"}B and Figure [S5](#cas13859-sup-0005){ref-type="supplementary-material"}A). Among these, *NOTCH1* (72.7%) mutations were also frequently observed in relapsed T‐ALL, but *FBXW7*,*DNM2* and *PHF6* mutations were less frequent. As previously reported, *NT5C2* mutations (27.3%) were predominantly detected in relapse samples (Figure [1](#cas13859-fig-0001){ref-type="fig"}C and Figure [S5](#cas13859-sup-0005){ref-type="supplementary-material"}B). An overrepresentation of C\>T and C\>A transitions was observed in samples at both diagnosis and relapse (Figure [S6](#cas13859-sup-0006){ref-type="supplementary-material"}).

![Whole--exome sequencing (WXS) data of 11 cases of relapse‐diagnosis‐remission trios and 19 matched T‐cell acute lymphoblastic leukemia (T‐ALL) remission pairs. A, The number of mutations detected by WXS without synonymous mutations. More mutations were observed in relapse samples (*P *=* *.014; Student\'s *t* test). Genes recurrently mutated in (B) 30 T‐ALL samples at diagnosis and (C) 11 relapse samples. The most common mutations were detected in *NOTCH1* in both diagnosis (66.7%) and relapse (36.6%) samples. *NT5C2* (27.3%) mutations were present only in relapse samples. n.s., not significant](CAS-110-784-g001){#cas13859-fig-0001}

###### 

Clinical characteristics of relapse and non--relapse cases at diagnosis

  Characteristics                                                                 Non--relapse cases (N = 18)   Relapse cases (N = 12)   Fisher\'s exact test
  ------------------------------------------------------------------------------- ----------------------------- ------------------------ ----------------------
  Sex                                                                                                                                    n.s.
  Male                                                                            13 (72.2)                     10 (90.9)                
  Female                                                                          5 (27.8)                      1 (9.1)                  
  Not available                                                                   0                             1                        
  Age at diagnosis                                                                                                                       n.s.
  1 to 9 y                                                                        11 (61.1)                     5 (41.7)                 
  ≥10 y                                                                           7 (38.9)                      7 (58.3)                 
  Not available                                                                   0                             0                        
  WBC counts at diagnosis                                                                                                                n.s.
  \<100 000/μL                                                                    12 (66.7)                     4 (33.3)                 
  ≥100 000/μL                                                                     6 (33.3)                      8 (66.7)                 
  Not available                                                                   0                             0                        
  Prednisolone response                                                                                                                  n.s.
  Good (day 8 WBC \<1000/μL)                                                      9 (52.9)                      8 (80.0)                 
  Poor (day 8 WBC ≥1000/μL)                                                       8 (47.1)                      2 (20.0)                 
  Not available                                                                   1                             2                        
  CNS involvement                                                                                                                        n.s.
  CNS‐1, CNS‐2                                                                    17 (94.4)                     10 (90.9)                
  CNS‐3                                                                           1 (5.6)                       1 (9.1)                  
  Not available                                                                   0                             1                        
  Mediastinal mass                                                                                                                       n.s.
  Yes                                                                             7 (38.9)                      7 (58.3)                 
  No                                                                              11 (61.1)                     5 (41.7)                 
  Not available                                                                   0                             0                        
  Previously analyzed expression cluster[a](#cas13859-note-0002){ref-type="fn"}                                                          
  *TAL1*‐RA                                                                       5 (33.3)                      4 (44.4)                 
  *TAL1*‐RB                                                                       2 (13.3)                      0 (0)                    
  TLX                                                                             3 (20.0)                      1 (11.1)                 
  ETP                                                                             4 (26.7)                      2 (22.2)                 
  *SPI1*‐fusion                                                                   1 (6.7)                       2 (22.2)                 
  Follow--up duration days (median)                                               507‐5427 (3069)               209‐3211 (750)           

CNS, central nervous system; ETP, early T‐cell precursor; WBC, white blood cell.

These 5 clusters were identified using whole--transcriptome sequencing based on expression profiles in our previous study.[6](#cas13859-bib-0006){ref-type="ref"} ETP, immature cluster showing similar expression profiles to early T‐cell precursor; *SPI1*‐fusion; *SPI1*‐highly expressed cluster with *SPI1* fusion; *TAL1*‐RA, *TAL1*‐highly expressed cluster with low gene mutation rate; *TAL1*‐RB, *TAL1*‐highly expressed cluster with high gene mutation rate; TLX, *TLX*1/*TLX3*‐highly expressed cluster.

John Wiley & Sons, Ltd

3.2. Germline mutations in predisposition genes detected in whole--exome sequencing {#cas13859-sec-0011}
-----------------------------------------------------------------------------------

We identified 3 missense germline variants, *FAP* ([NM_004460](NM_004460): K533X), *IDH1* ([NM_005896](NM_005896): F355V) and *RET* ([NM_020630](NM_020630): M848V), in 2 specimens (Table [S5](#cas13859-sup-0014){ref-type="supplementary-material"}). *FAP*, encoding a tumor suppressor involved in cell proliferation and survival, was truncated at exon 18. The *IDH1* variant was reported as one of the cancer predisposition tumor suppressor genes.[37](#cas13859-bib-0037){ref-type="ref"} The detected *IDH1* variant was predicted as a high risk factor for developing cancers according to the mutation assessor (<http://mutationassessor.org/v1/>), although no germline and somatic mutations have been reported at the same position. The mutation in *RET* was located in its kinase domain, which is consistent with previous reports.[37](#cas13859-bib-0037){ref-type="ref"} Importantly, neither family history of cancer nor underlying disease was observed in these cases.

3.3. Types of *NOTCH1* and *FBXW7* mutations observed in T‐cell acute lymphoblastic leukemia {#cas13859-sec-0012}
--------------------------------------------------------------------------------------------

We detected mutations leading to NOTCH1 signaling activation (*NOTCH1* and/or *FBXW7* alterations) in 22 out of 30 (73.3%) and 8 out of 11 (72.7%) samples at diagnosis and relapse, respectively (Figure [2](#cas13859-fig-0002){ref-type="fig"}A and Table [\[Link\]](#cas13859-sup-0012){ref-type="supplementary-material"}, [\[Link\]](#cas13859-sup-0013){ref-type="supplementary-material"}). Both LIA and ID mutation types were detected in 11 out of 30 (36.7%) and 3 out of 11 (27.3%) samples at diagnosis and relapse, respectively (Figure [2](#cas13859-fig-0002){ref-type="fig"}A,B and Figure [\[Link\]](#cas13859-sup-0007){ref-type="supplementary-material"}, [\[Link\]](#cas13859-sup-0008){ref-type="supplementary-material"}). These mutations were mutually exclusive within each LIA and ID pattern, except for 1 sample that harbored mutations with low allele frequencies less than 15% (Figure [2](#cas13859-fig-0002){ref-type="fig"}A). In our cohort, HD‐SNVs were the most frequent (40.0%; 12 out of 30 samples), followed by PEST alterations (33.3%; 10 out of 30 samples). In--frame internal duplication in exon 28, known as juxta‐membrane expansion (Dup), intragenic *NOTCH1* deletion (Del‐N) and SNV at 3′UTR (UTR) were each detected in 1 sample (Table [2](#cas13859-tbl-0002){ref-type="table"}). The frequency of PEST alterations in relapsed cases of diagnosis samples (7 out of 12; 58.3%) was significantly higher than that in non--relapsed cases (3 out of 18; 16.7%) (*P *=* *.045; Figure [2](#cas13859-fig-0002){ref-type="fig"}C and Table [2](#cas13859-tbl-0002){ref-type="table"}). We also analyzed the WXS data of 200 T‐ALL cases generated by Therapeutically Applicable Research to Generate Effective Treatment (TARGET)[7](#cas13859-bib-0007){ref-type="ref"}; however, no predominance of PEST alterations was observed in relapsed cases (Table [S6](#cas13859-sup-0015){ref-type="supplementary-material"}).

![Characteristics of *NOTCH1* and *FBXW7* alterations leading to NOTCH1 signaling activation. A, An overview of *NOTCH1* and *FBXW7* mutations in 30 T‐cell acute lymphoblastic leukemia (T‐ALL) samples at diagnosis. Detected mutation types (HD‐SNV, Indel, Dup, Del‐N, PEST,UTR and FBXW7) and patterns (LIA and ID) are colored. Each T‐ALL case did not possess mutations of multiple types within the same patterns (LIA or ID) except minor mutation. B, Frequencies of *NOTCH1* or *FBXW7* mutations detected at diagnosis and relapse. C, Frequencies of *NOTCH1* or *FBXW7* mutations detected at diagnosis in non--relapsed and relapsed cases. Mutations in the PEST domain were detected significantly more frequently in relapsed cases than in non--relapsed cases (*P *=* *.045; Fisher\'s exact test). Del‐N, intragenic *NOTCH1* deletion; Dup, in--frame internal duplication in exon 28; HD‐SNV, single nucleotide variations in the heterodimerization domain; ID, impaired degradation; Indel, small in--frame insertions or deletions in the HD domain; LIA, ligand--independent activation; m, minor mutation (VAF \<15%); PEST, proline, glutamic acid, serine, and threonine; UTR,SNV in 3′ untranslated region](CAS-110-784-g002){#cas13859-fig-0002}

###### 

Frequencies of *NOTCH1* or *FBXW7* alterations detected at diagnosis of T‐ALL

                                                          Non--relapsed cases (%) n = 18                    Relapsed cases (%) n = 12                         *P*‐value   References
  ------------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ----------- ------------------------------------------------------------------------------------
  LIA, ligand--independent activation.                                                                                                                                    
  *NOTCH1* HD domain non--synonymous mutation (HD‐SNV)    8 (44.4)                                          4 (33.3)[a](#cas13859-note-0003){ref-type="fn"}   .71         [10](#cas13859-bib-0010){ref-type="ref"}
  *NOTCH1* HD domain non--frameshift indel (Indel)        1 (5.6)                                           2 (16.7)[c](#cas13859-note-0005){ref-type="fn"}   .55         [10](#cas13859-bib-0010){ref-type="ref"}
  *NOTCH1* internal duplication (Dup)                     0 (0)                                             1 (8.3)[c](#cas13859-note-0005){ref-type="fn"}    .4          [13](#cas13859-bib-0013){ref-type="ref"}
  Deletion in extracellular domains of *NOTCH1* (Del‐N)   1 (5.6)                                           0 (0)                                             ---         [14](#cas13859-bib-0014){ref-type="ref"}, [15](#cas13859-bib-0015){ref-type="ref"}
  *NOTCH1* fusion (Fusion)                                0 (0)                                             0 (0)                                             ---         [16](#cas13859-bib-0016){ref-type="ref"}
  Impaired degradation: ID                                                                                                                                                
  *NOTCH1* PEST domain truncation (PEST)                  3 (16.7)[b](#cas13859-note-0004){ref-type="fn"}   7 (58.3)                                          .045        [10](#cas13859-bib-0010){ref-type="ref"}
  *NOTCH1* 3′UTR region mutation (UTR)                    0 (0)                                             1 (8.3)[a](#cas13859-note-0003){ref-type="fn"}    ---         [17](#cas13859-bib-0017){ref-type="ref"}
  *FBXW7* mutation (FBXW7)                                5 (27.8)                                          1 (8.3)[c](#cas13859-note-0005){ref-type="fn"}    .35         [11](#cas13859-bib-0011){ref-type="ref"}, [12](#cas13859-bib-0012){ref-type="ref"}

All cases had PEST as well.

All cases had HD‐SNV as well.

No cases had PEST additionally.

John Wiley & Sons, Ltd

3.4. Clonal analysis of samples at diagnosis and relapse identified mutational "switching" of *NOTCH1* {#cas13859-sec-0013}
------------------------------------------------------------------------------------------------------

Based on the results of amplicon--based deep sequencing of all mutations detected by WXS, we evaluated the clonal evolution of T‐ALL relapses using accurate VAFs of each detected mutation. The clonal analysis of diagnosis and relapse samples identified 3 different types of clonal evolution at relapse in T‐ALL samples: acquired new mutations (VAF \>.01) at relapse which were not detected or very low level (VAF \<.01) at diagnosis without losing any mutations (VAF \>.01) (type 1; Figure [3](#cas13859-fig-0003){ref-type="fig"}A), acquired new mutations (VAF \>.01) and lost some mutations (VAF \<.01) at relapse (type 2; Figure [3](#cas13859-fig-0003){ref-type="fig"}B); and no mutations were acquired (VAF \>.01) or lost (VAF \<.01) at relapse (type 3; Figure [3](#cas13859-fig-0003){ref-type="fig"}C).

![Depictions of clonal evolution from diagnosis to relapse in each relapse type. A‐D, Clonal analysis in the representative case (TALL001) of relapse type 1, which acquired additional mutations at relapse in addition to all detected mutations at diagnosis. E‐H, Clonal analysis in the representative case (TALL031) of relapse type 2. Several mutations presented in the major clone at diagnosis were lost, and additional mutations were acquired at relapse. I‐L, Clonal analysis of relapse type 3. Same gene mutations were observed at both diagnosis and relapse in type 3 samples. A,E,I, Observed VAF of each mutation are shown in diagonal plots. Red dots indicate *NOTCH1*. B,F,J, VAF of detected mutations in each clone are indicated. C,G,K, Schematic description of population in each clone at diagnosis and relapse is shown. D,H,L, Schematic description of clonality in each clone at diagnosis (D) and relapse (R) is shown in phylogenetic trees. Detected mutations in each clone are listed. VAF, variant allele frequency](CAS-110-784-g003){#cas13859-fig-0003}

Type 1 clonal evolution at relapse was observed in 3 samples (TALL001, TALL015 and TALL026). These samples acquired additional mutations later in the process of leukemogenesis at relapse. All mutations detected at diagnosis were also detected in relapse samples (Figure [3](#cas13859-fig-0003){ref-type="fig"}A‐D). *NOTCH1* and/or *FBXW7* alterations were detected in the common major clone (VAF \>.15, both diagnosis and relapse) in TALL001 and TALL015, and none of these 3 type 1 cases acquired additional *NOTCH1* and/or *FBXW7* alterations at relapse. Unlike the previous report,[26](#cas13859-bib-0026){ref-type="ref"} all cases of type 1 clonal evolution relapsed after 12 months of diagnosis (Figure [S9](#cas13859-sup-0009){ref-type="supplementary-material"}A).

In type 2 clonal evolution, several mutations detected in the major clone at diagnosis were lost and additional new mutations were acquired at relapse (Figure [3](#cas13859-fig-0003){ref-type="fig"}E‐H). Type 2 clonal evolution was observed in 7 cases (TALL002, TALL003, TALL005, TALL017, TALL023, TALL029 and TALL031), of which PEST alterations were identified in 6 cases at relapse. Three cases also acquired HD‐SNVs and *GATA3* mutations at the same time. In TALL031, PEST alteration was detected in the common major clone both at diagnosis and relapse. The other major clone (Clone 2) at diagnosis disappeared and the new major clone (Clone 3) with the acquired *NOTCH1* mutation (HD‐SNV) expanded at relapse (Figure [3](#cas13859-fig-0003){ref-type="fig"}E). In contrast, in TALL029, both the HD‐SNV and PEST alterations were detected at diagnosis; of these, the HD‐SNV disappeared and only the PEST alteration was identified with other acquired mutations at relapse.

It should be noted that we identified *NOTCH1* "switching" in 2 cases (TALL017 and TALL023) with type 2 clonal evolution, showing different *NOTCH1* mutations at diagnosis and relapse. In these cases, the dominant clone at diagnosis with *NOTCH1* mutations had disappeared at relapse with an expansion of a new dominant clone with a different *NOTCH1* mutation derived from the same ancestor clone (Figure [4](#cas13859-fig-0004){ref-type="fig"} and Figure [S1](#cas13859-sup-0001){ref-type="supplementary-material"}). For example, TALL017 harbored 3 *NOTCH1* mutations at diagnosis, PEST alteration in Clone 1 (common major clone, VAF \>.15 both at diagnosis and at relapse), and 2 independent HD‐SNVs in Clone 2 (VAF \>.15 at diagnosis) and Clone 3 (VAF \<.15 at diagnosis), respectively (Figure [4](#cas13859-fig-0004){ref-type="fig"}A). The treatment of T‐ALL at diagnosis might eradicate 1 of the HD‐SNVs present in Clone 2. The other HD‐SNV in Clone 3 expanded as a "switched" major clone (VAF \>.15) at relapse (Figure [4](#cas13859-fig-0004){ref-type="fig"}A‐D). In addition to *NOTCH1* expansion, *NT5C2* mutation was also acquired in this "switched" clone, and seemed to have a selective advantage for relapse (Figure [4](#cas13859-fig-0004){ref-type="fig"}D). Intriguingly, TALL023 was the other case of *NOTCH1* "switching" that developed LCH from a common clone in diagnostic T‐ALL (Figure [4](#cas13859-fig-0004){ref-type="fig"}E‐H and Figure [S1](#cas13859-sup-0001){ref-type="supplementary-material"}). In the T‐ALL sample, 2 *NOTCH1* mutations (both with ID pattern) were identified in the UTR (Clone 2, VAF = .19) and the other in the PEST domain (Clone 4, VAF = .07). In the LCH sample, only the PEST alteration was observed, suggesting that the mutation in the UTR disappeared after the initial T‐ALL treatment. Moreover, the clone with PEST alteration (Clone 4) expanded as a "switched" major clone (VAF \>.15) at LCH from a minor subclone (VAF \<.15) in the T‐ALL sample at diagnosis (Figure [4](#cas13859-fig-0004){ref-type="fig"}E‐H). In this case, the acquisition and expansion of *BRAF* alteration, important for the pathogenesis of LCH, were observed at LCH in addition to *NOTCH1* "switching." By contrast, the *GATA3* mutation involved in T‐ALL pathogenesis was eradicated. Using multiplex PCR for the detection of TCR rearrangement between diagnosis and relapse samples of these "switching" cases, we confirmed that diagnosis‐relapse paired samples had the same TCR rearrangement pattern (Figure [S1](#cas13859-sup-0001){ref-type="supplementary-material"}). Intriguingly, we detected multiple waves in TALL017 that might indicate the existence of multiple clones harboring different TCR rearrangements within the tumor. This is consistent with the ClonEvol analysis result that TALL017 had 2 major subclones at relapse originated from the same ancestor clone (Figure [4](#cas13859-fig-0004){ref-type="fig"}A‐D). We further investigated previously reported paired diagnosis‐relapse T‐ALL cases and found another *NOTCH1* "switching" case (T‐ALL‐H‐S00285) out of 13 paired cases.[26](#cas13859-bib-0026){ref-type="ref"} In this case, 2 *NOTCH1* mutations (both HD‐SNV) were detected at diagnosis. One in minor subclones had disappeared (VAF = from .12 to .0003) and the other HD‐SNV in major clones was replaced (VAF = from .33 to .04) by newly expanded HD‐SNV at relapse (VAF = .26), which was not detected at diagnosis (VAF = .0008).

![Schematic description of clonal evolution in the cases of *NOTCH1* "switching." Clonal analysis in TALL017 (A‐D) and TALL023 (E‐H) is shown; representative cases of *NOTCH1* "switching" detecting different *NOTCH1* mutations between T‐ALL diagnosis and relapse. A,E, Observed VAF of each mutation are shown in diagonal plots. Red dots indicate *NOTCH1*. Each clone was estimated based on the results of PyClone and SciClone. B,F, VAF of detected mutations in each clone are indicated. D,H, Schematic description of clonality in each clone at diagnosis (D) and relapse (R) is shown in phylogenetic trees. Detected mutations in each clone are listed. VAF, variant allele frequency](CAS-110-784-g004){#cas13859-fig-0004}

Type 3 clonal evolution at relapse was observed in 1 case (TALL018). In this case, the same gene mutations were observed in both diagnosis and relapse samples (Figure [3](#cas13859-fig-0003){ref-type="fig"}I‐L). Insufficient treatment of T‐ALL at diagnosis was considered to induce expansion of the same clone in this type of relapse. In this case, relapse occurred within 10 months of diagnosis. TALL018 was treated without MRD--based protocol. This case was assumed to remain MRD positive after remission induction. The mean VAF of all validated mutations in the corresponding normal sample was above 10^−3^ level at the end of the induction (mean VAF = .0026; Figure [S9](#cas13859-sup-0009){ref-type="supplementary-material"}B).

4. DISCUSSION {#cas13859-sec-0014}
=============

Based on the results of clonal analysis of samples at diagnosis and relapse, we identified *NOTCH1* "switching" characterized by different *NOTCH1* mutations in a major clone between diagnosis and relapse samples. This *NOTCH1* "switching" has been previously reported using WAVE chromatograms.[38](#cas13859-bib-0038){ref-type="ref"} In chronic lymphocytic leukemia (CLL), ultra--deep next--generation sequencing demonstrated similar changes of *TP53* mutations in relapse and re--relapse samples.[39](#cas13859-bib-0039){ref-type="ref"} Dysfunction of TP53 is considered the major cause of genomic instability in CLL cells, leading to resistance to treatment.[40](#cas13859-bib-0040){ref-type="ref"}, [41](#cas13859-bib-0041){ref-type="ref"} Taken together, "switching" of *NOTCH1* mutations indicates that NOTCH1 plays an important role in both leukemogenesis and progression. According to previous studies,[10](#cas13859-bib-0010){ref-type="ref"}, [42](#cas13859-bib-0042){ref-type="ref"} increased luciferase activity by HD‐SNV and PEST domain mutations seemed to be different depending on the position of mutations. These HD‐SNV and PEST domain mutations were recognized as a weak tumor initiator even when they existed in cis, because these mutations failed to efficiently initiate T‐ALL in mice. In contrast, they were reported to accelerate T‐ALL with other driver mutations such as *KRAS* (detected in "switched" TALL023 sample), and they showed addiction to NOTCH1 signaling. Thus, we estimate that functional advantage in replacement of *NOTCH1* mutations (HD‐SNV to HD‐SNV in TALL017 and UTR to PEST in TALL023, respectively) in "switched" T‐ALL cases itself was not big, but the existence of *NOTCH1* mutations in the "switched" clone might be important for selection advantage in relapse as the secondary event. Furthermore, we identified the acquisition of *NT5C2* and *BRAF* mutations in cases of "switched" clones, respectively. *NT5C2* mutation involves in clonal evolution during disease progression and relapse with induction of resistance to 6‐mercaptopurine.[8](#cas13859-bib-0008){ref-type="ref"}, [9](#cas13859-bib-0009){ref-type="ref"}, [43](#cas13859-bib-0043){ref-type="ref"} Mutations in MAPK pathway, including *BRAF*, were frequently observed in LCH.[44](#cas13859-bib-0044){ref-type="ref"} Acquisition of these mutations in "switched" clones might be associated with selective advantage during tumor clonal evolution.

All 3 cases representing *NOTCH1* "switching" or expansion at relapse contained the PEST alteration in the major clone. In TALL023, the case of *NOTCH1* "switching," the PEST alteration at relapse was enriched from minor populations (VAF = from .07 to .42), and the UTR--specific mutation was eradicated (VAF = from .19 to 0). This suggests that NOTCH1 pathway activation via PEST alterations might offer a selection advantage in this case. In CLL, *NOTCH1* mutations occur almost exclusively in PEST and are associated with poor prognosis.[45](#cas13859-bib-0045){ref-type="ref"} Furthermore, PEST alterations were predominantly detected in diagnosis samples of relapsed cases rather than in non--relapsed cases, although this enrichment of PEST alterations in relapse cases was not confirmed in TARGET data. These results imply that PEST alterations are involved in the progression and early relapse of T‐ALL. However, further research is warranted to decide the impact of PEST alterations in T‐ALL.

The limitations of this study include its small sample size, treatment without MRD--based protocol, and its retrospective design in a single facility, leading to a selection bias. Nonetheless, mutations detected in this study using WXS of 30 T‐ALL cases are consistent with previous reports.[6](#cas13859-bib-0006){ref-type="ref"}, [7](#cas13859-bib-0007){ref-type="ref"}, [46](#cas13859-bib-0046){ref-type="ref"}, [47](#cas13859-bib-0047){ref-type="ref"} Recent improvement in survival might be largely due to MRD--based risk stratification. Thus, further analysis is required to confirm the relevance of PEST mutations in the progression to relapse using large cohorts with or without MRD--based protocol.

In conclusion, we described that "switching" of *NOTCH1* mutations demonstrates the importance of NOTCH1 signaling activation not only in the development but also in the progression of T‐ALL. In addition, mutations in the PEST domain of *NOTCH1* may be involved in T‐ALL relapse in pediatric cases. Our results might be helpful for developing a new anti--NOTCH1 therapeutic strategy for refractory or relapsed T‐ALL patients, although further studies are warranted.
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